Phase 3 trials are extending immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → combinations and cellular therapies. Fianlimab (anti-LAG-3) combined with cemiplimab (anti-PD-1) is being tested against pembrolizumab in untreated unresectable or metastatic melanoma. SUPRAME compares the engineered T-cell receptor therapy IMA203 against several investigator's choice options in previously treated cutaneous melanoma. A Phase 4 ctDNA-guided trial tests addition of ipilimumab to nivolumab and relatlimab based on circulating tumor DNA. Phase 3 work is also assessing intermittent versus continuous PD-1 therapy in metastatic disease. Earlier studies include TIL therapies engineered with membrane-bound IL-15, PRAME-targeted T-cell receptor NK cells, novel RNA lipid particle vaccines, oncolytic and bispecific approaches such as REGN10597 with cemiplimab, and the combination of fianlimab, cemiplimab, and ipilimumab. For mucosal melanoma, an underserved subtype, adjuvant short-course radiotherapy plus chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and a PD-1 inhibitor is being tested. Laboratory work has identified BET inhibitors as immunogenicity boosters, KLRG1 as a new checkpoint target, mechanisms of drug-tolerant persister cell formation, and immune signatures that predict non-response to PD-1 therapy.
Where the evidence stands
Single-agent and combination immune checkpoint blockade and BRAF and MEK inhibition are firmly established with overall survivalThe percentage of patients still alive after a set period — a key clinical trial endpoint.Click for full explanation → benefits and have changed long-term outcomes in advanced melanoma. TIL therapy with lifileucel is now an approved option for refractory disease, the first cellular therapy in a solid tumor. The next wave, anti-LAG-3 combinations, engineered T-cell receptor cell therapies, and radioligand or bispecific approaches, is in late Phase 3. Mucosal and uveal melanoma remain harder to treat, with targeted approaches in earlier development.
What this means for people affected
Cutaneous melanoma has seen one of the most dramatic survival improvements in oncology over the past 15 years, with long-term survival now possible in metastatic disease for many people receiving immune checkpoint blockade. BRAF mutationA change in DNA sequence that can drive cancer development.Click for full explanation → testing is standard at diagnosis of advanced disease and shapes targeted therapyDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → decisions. Resistance to immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → is the central remaining challenge, and several trials, including TIL therapies, anti-LAG-3 combinations, and engineered cell therapies, address this. Mucosal and uveal melanoma have fewer options and generally warrant clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → consideration. Adjuvant and neoadjuvant immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → approaches for resectable disease are also active areas of research.
Last updated May 1, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: February 1, 2030
Testing Combination Therapy for Melanoma Brain Metastases
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying a combination of medications (relatlimab, nivolumab, and ipilimumab) for patients with melanoma that has spread to the brain. The trial is currently recruiting participants. The goal is to see how well this treatment works for people with this condition.
Why it matters: This trial may help doctors find a more effective treatment for patients with melanoma that has spread to the brain.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: December 31, 2027
Testing Combination Therapy for Metastatic Melanoma
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the combination of two treatments, PD-1 antibody therapy and Infliximab, for people with metastatic melanoma. The trial is currently active but not recruiting participants. The goal is to see if this combination is safe and effective.
Why it matters: This trial may help doctors understand if a new combination of treatments can improve outcomes for people with metastatic melanoma.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 13, 2026
New Delivery Method for Cancer Treatment Shows Promise
Researchers developed a way to deliver two antibodies directly to the brain to treat melanoma that has spread to the brain. They used a sweetener called glycerol to help the antibodies get past the brain's protective barrier. In lab experiments, this method was able to deliver the antibodies more effectively and helped the body's immune system fight the cancer.
Why it matters: This finding could lead to new and more effective treatments for melanoma that has spread to the brain.
This study was conducted in the lab and has not been tested in humans yet.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: August 1, 2030
Study of ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → for High-Risk Melanoma
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is investigating the effectiveness of a combination of two immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → drugs, Ipilimumab and Nivolumab, in treating patients with high-risk, recurrent melanoma that can be surgically removed. The trial is currently recruiting participants. The results of this study are not yet available.
Why it matters: This trial may help doctors better understand how to treat patients with high-risk melanoma.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: July 31, 2028
Testing Nivolumab and Relatlimab for Melanoma Brain Metastases
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the combination of Nivolumab and Relatlimab in patients with active melanoma that has spread to the brain. The trial is currently recruiting participants. The goal is to learn more about the safety and effectiveness of this treatment.
Why it matters: This trial aims to improve treatment options for people with melanoma that has spread to the brain.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 13, 2026
Researchers Identify MicroRNAs That May Help Regulate Uveal Melanoma
Scientists studied how a protein called SOX10 affects microRNAs in uveal melanoma cells. They found 17 microRNAs that may play a role in regulating cancer pathways. These microRNAs could potentially help slow down the growth of uveal melanoma.
Why it matters: This finding could help researchers better understand how uveal melanoma develops and progresses, which may lead to new treatment options.
This study was conducted in lab experiments using cells, not in people.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 13, 2026
New Method Helps Identify Cancer Risk Factors
Researchers developed a new statistical method to analyze cancer data and identify important risk factors. They applied this method to data from the National Cancer Institute and found some risk factors that may be associated with melanoma. However, more research is needed to confirm these findings.
Why it matters: This finding could help scientists better understand what contributes to melanoma and inform future research.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 13, 2026
Researchers Investigate Role of ICMT in BRAF-Driven Cancers
Researchers studied how a protein called ICMT helps cancer cells grow in BRAF-driven melanoma. They found that ICMT helps another protein called INPP5E attach to cell membranes, which is important for cancer growth. In lab experiments, they showed that blocking ICMT can slow down cancer cell growth.
Why it matters: This finding could help scientists understand how BRAF-driven cancers work and potentially lead to new treatments.
Efficacy
Genetic and pharmacologic ICMT inhibition suppressed proliferation and invasion in BRAF-mutant melanoma cells and reduced tumor growth in xenografts and mice.
This study was conducted in lab experiments and has not been tested in humans yet.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 12, 2026
Understanding Melanoma Tumors with Complex Genetic Makeup
Researchers created a computer model to study how melanoma tumors develop and change over time. They found that immune cells play a strong role in shaping the genetic diversity of these tumors. The model also showed that the movement of cancer cells can create complex tumor shapes.
Why it matters: This finding could help scientists better understand how melanoma tumors evolve and how they respond to treatments.
This study used a computer model and did not involve human patients.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 12, 2026
Sun Exposure and Skin Color May Affect Melanoma Prognosis
Researchers looked at how sun exposure and skin color affect the prognosis of people with advanced melanoma. They found that people who had more severe sunburns as children and lighter skin may have a better chance of survival. However, the study was small and more research is needed to confirm these results.
Why it matters: This finding could help doctors better understand how to treat people with advanced melanoma and may lead to new research on the relationship between sun exposure and skin color and cancer prognosis.
Efficacy
Patients who reported >5 severe sunburns during childhood had a significantly decreased risk of death compared to patients with 0-1 sunburn (HR 0.46, CI 0.25-0.85, p=0.013).
The study population was small, with only 210 patients.
Phase 1 TrialFirst-in-human trial. Focuses on safety and dosing in small groups.Est. completion: December 30, 2027
Testing LBL-024 for Advanced Melanoma Treatment
Researchers are studying LBL-024 as a treatment for advanced melanoma, either alone or combined with other medications. The trial is currently recruiting participants. The goal is to learn more about the safety and effectiveness of LBL-024 in this patient group.
Why it matters: This trial may help doctors understand how to use LBL-024 to treat advanced melanoma.
This trial is currently recruiting participants and is in its early stages.
Phase 2 TrialTests early effectiveness in a larger group after phase 1 safety is established.Est. completion: January 1, 2027
Ensartinib Treatment for Melanoma Patients with ALK Alterations
This clinical trialA research study that tests a medical intervention in human volunteers.Click for full explanation → is studying the effectiveness of Ensartinib in treating patients with melanoma who have ALK alterations. The trial is currently active but not recruiting participants. The results of this trial are not yet available.
Why it matters: This trial aims to determine if Ensartinib can provide a treatment option for patients with melanoma and ALK alterations.
Liquid Biopsy Multi-Omics and BiomarkerA measurable biological signal used to detect disease or predict treatment response.Click for full explanation → Development in Melanoma
